(firstQuint)Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC.

 A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with stage IIIB,IV or recurrent NSCLC of non-squamous.

 the study will randomize about 436 patients at a 1:1 ratio to 2 treatment arms.

 The study is divided 4 phase, screening, combination treatment, maintenance and follow up.

.

 Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC@highlight

A randomized, double blind, multicenter phase3 study .

